SEC-sourced researchBeta
BTAIQ
BioXcel Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001720893
- Exchange
- OTC
- Business activity
- Pharmaceutical Preparations · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Nov 17, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 2,266,000.0000 | Mar 27, 2026 |
| December 2025 | 642,000.0000 | Mar 27, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 642,000.0000 | -69,897,000.0000 | -57,615,000.0000 | 44,916,000.0000 | 140,379,000.0000 | Mar 27, 2026 |
| December 2024 | 2,266,000.0000 | -59,599,000.0000 | -72,027,000.0000 | 38,338,000.0000 | 131,439,000.0000 | Mar 27, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
20/100
Profitability0
Growth0
Balance sheet0
Cash generation0
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $642K | Jan 1, 2025 – Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $2.27M | Jan 1, 2024 – Dec 31, 2024 | Mar 27, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$69.9M | Jan 1, 2025 – Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$57.62M | Jan 1, 2025 – Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Total assetsAssets | $44.92M | Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Total liabilitiesLiabilities | $140.38M | Dec 31, 2025 | Mar 27, 2026 | 10-K |